Sonoma Pharmaceuticals, Inc. SNOA
Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006
we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc.
Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A.
de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal year end is March 31. Our corporate telephone number is (800) 759-9305.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M |
| Cost of revenue | $12.1M | $8.8M | $8.0M | $8.8M | $8.6M | $12.1M | $9.8M | $10.1M | $9.3M | $7.2M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M | $8.1M | $8.9M | $7.3M | $5.7M |
| R&D | $2.3M | $1.8M | $1.9M | $207.0K | $125.0K | $555.0K | $1.3M | $1.5M | $1.6M | $1.6M |
| SG&A | $7.6M | $7.4M | $7.6M | $8.8M | $9.8M | $9.5M | $14.2M | $18.6M | $19.9M | $17.1M |
| Total operating expenses | $9.9M | $9.2M | $9.4M | $9.0M | $9.9M | $10.0M | $15.5M | $20.1M | $21.5M | $18.6M |
| Operating income | -$2.5M | -$3.7M | -$4.7M | -$4.6M | -$5.9M | -$3.4M | -$7.4M | -$11.3M | -$14.2M | -$13.0M |
| Interest expense | — | — | — | $16.0K | $10.0K | $4.0K | $16.0K | $33.0K | $40.0K | $3.0K |
| Pre-tax income | -$3.4M | -$2.9M | -$5.0M | -$5.2M | -$5.4M | -$3.9M | -$3.5M | -$11.3M | -$14.3M | -$12.9M |
| Income tax | $244.0K | $550.0K | $196.0K | $33.0K | $332.0K | $713.0K | $29.0K | $458.0K | $50.0K | $4.3M |
| Net income | $3.2K | $3.5K | $4.8K | -$5.2M | -$5.1M | -$4.0M | -$3.3M | -$11.8M | -$14.3M | $9.3M |
| EPS, basic | -1.89 | -2.79 | -10.63 | -1.52 | -1.92 | — | — | — | — | — |
| EPS, diluted | -1.89 | -2.79 | -10.63 | -1.52 | -1.92 | -1.97 | -2.24 | -12.77 | -28.49 | 2.20 |
| Shares, diluted (wtd. avg.) | $1.7M | $1.2M | $455.0K | $3.4M | $2.7K | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.4M | $5.4M | $3.1M | $3.8M | $7.4M | $4.2M | $3.7M | $3.7M | $10.1M | $17.5M |
| Receivables | $2.5M | $2.2M | $2.9M | $2.6M | $2.4M | $2.8M | $4.0M | $3.5M | $1.5M | $2.1M |
| Inventory | $3.7M | $2.9M | $2.7M | $2.9M | $2.7M | $2.5M | $2.2M | $3.4M | $2.9M | $2.2M |
| Total current assets | $12.1M | $12.6M | $12.5M | $13.8M | $16.4M | $13.0M | $12.3M | $12.5M | $16.3M | $22.6M |
| Property, plant and equipment | $310.0K | $225.0K | $365.0K | $488.0K | $320.0K | $360.0K | $365.0K | $727.0K | $1.1M | $1.2M |
| Total assets | $14.0M | $13.7M | $14.7M | $16.2M | $18.8M | $15.0M | $14.6M | $14.4M | $19.2M | $25.5M |
| Accounts payable | $1.9M | $953.0K | $607.0K | $841.0K | $1.6M | $1.8M | $2.1M | $1.3M | $1.3M | $1.3M |
| Short-term debt | $222.0K | $220.0K | $323.0K | $431.0K | — | $596.0K | $481.0K | $322.0K | $230.0K | $123.0K |
| Total current liabilities | $4.8M | $4.1M | $3.7M | $3.7M | $5.8M | $4.1M | $4.7M | $3.6M | $3.3M | $3.3M |
| Long-term debt | — | — | — | — | $0 | $1.3M | $0 | $12.0K | $32.0K | $45.0K |
| Total liabilities | $10.9M | $9.3M | $8.6M | $8.3M | $10.1M | $9.6M | $8.9M | $4.0M | $3.9M | $4.0M |
| Retained earnings | -$201.0M | -$197.8M | -$194.3M | -$189.5M | -$184.4M | -$179.3M | -$175.3M | -$169.2M | -$157.4M | -$143.1M |
| Total equity | $3.1M | $4.4M | $6.1M | $8.0M | $8.7M | $5.4M | $5.6M | $7.8M | $15.3M | $21.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.9M | -$88.0K | -$2.4M | -$6.2M | -$4.2M | -$3.4M | -$4.6M | -$11.7M | -$12.4M | -$8.2M |
| Depreciation and amortisation | $139.0K | $138.0K | $176.0K | $125.0K | $186.0K | $227.0K | $312.0K | $453.0K | $490.0K | $248.0K |
| Stock-based compensation | $255.0K | $224.0K | $516.0K | $669.0K | $382.0K | $371.0K | $839.0K | $1.6M | $2.5M | $2.1M |
| Capital expenditure | $192.0K | $80.0K | $2.0K | $269.0K | $137.0K | $179.0K | $206.0K | $100.0K | $187.0K | $394.0K |
| Investing cash flow | -$192.0K | -$80.0K | -$2.0K | -$258.0K | -$99.0K | $388.0K | $3.6M | -$131.0K | -$201.0K | $18.2M |
| Financing cash flow | $477.0K | $3.0M | $1.7M | $2.5M | $7.4M | $3.3M | $1.0M | $5.5M | $5.2M | -$32.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-005810.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |